MX2021015661A - Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes. - Google Patents

Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes.

Info

Publication number
MX2021015661A
MX2021015661A MX2021015661A MX2021015661A MX2021015661A MX 2021015661 A MX2021015661 A MX 2021015661A MX 2021015661 A MX2021015661 A MX 2021015661A MX 2021015661 A MX2021015661 A MX 2021015661A MX 2021015661 A MX2021015661 A MX 2021015661A
Authority
MX
Mexico
Prior art keywords
preventing
promoting
treating
compositions
diabetes
Prior art date
Application number
MX2021015661A
Other languages
English (en)
Inventor
Gabriel Gojon-Zorrilla
Gabriel Gojon-Romanillos
Original Assignee
Molecule X Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecule X Llc filed Critical Molecule X Llc
Publication of MX2021015661A publication Critical patent/MX2021015661A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings

Abstract

Se divulgan cepas equipos que incluyen un desacoplador químico, tal como tirfostina 9 o su precursor o sal, y composiciones que incluyen un desacoplador químico, tal como tirfostina 9 en combinación con uno o más agentes terapéuticos, por ejemplo, L-carnitina, que son útiles, por ejemplo, en el tratamiento de la obesidad, la prevención del aumento de peso, la promoción de la pérdida de peso/adelgazamiento, y/o el tratamiento o la prevención del desarrollo de diabetes.
MX2021015661A 2014-07-03 2017-01-04 Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes. MX2021015661A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462020797P 2014-07-03 2014-07-03
US201562127111P 2015-03-02 2015-03-02

Publications (1)

Publication Number Publication Date
MX2021015661A true MX2021015661A (es) 2022-02-03

Family

ID=55016229

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017000222A MX2017000222A (es) 2014-07-03 2015-07-02 Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes.
MX2021015661A MX2021015661A (es) 2014-07-03 2017-01-04 Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017000222A MX2017000222A (es) 2014-07-03 2015-07-02 Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes.

Country Status (17)

Country Link
US (3) US10849872B2 (es)
EP (1) EP3164125B8 (es)
JP (2) JP6887252B2 (es)
CN (2) CN113387836A (es)
AU (2) AU2015283905B2 (es)
BR (1) BR112016030983A8 (es)
CA (1) CA2954004C (es)
CO (1) CO2017001025A2 (es)
DK (1) DK3164125T3 (es)
ES (1) ES2965033T3 (es)
FI (1) FI3164125T3 (es)
HR (1) HRP20231572T1 (es)
MX (2) MX2017000222A (es)
PE (1) PE20170470A1 (es)
PT (1) PT3164125T (es)
RU (1) RU2745440C2 (es)
WO (1) WO2016004363A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
BR112019010607B1 (pt) 2016-11-29 2023-10-31 University Of Iowa Research Foundation Uso de precursores de nad e composição compreendendo os referidos precursores
WO2018129258A1 (en) 2017-01-06 2018-07-12 Gencia Corporation Novel phenyl derivatives
CN107212225A (zh) * 2017-06-02 2017-09-29 陈玉霞 一种用于瘦身的玫瑰茄固体饮料及其制备方法
US10226442B2 (en) * 2017-07-10 2019-03-12 Syneurx International (Taiwan) Corp. Lithium salts of N-substituted glycine compounds and uses thereof
WO2019083297A1 (ko) * 2017-10-26 2019-05-02 주식회사 네비팜 간질환 예방 또는 치료용 의약 조성물
CN108272903A (zh) * 2018-03-15 2018-07-13 军事科学院军事医学研究院环境医学与作业医学研究所 一种减肥配方及其应用方法
CN112118855A (zh) * 2018-03-20 2020-12-22 爱瑟金股份有限公司 体重管理组合物
TWI710766B (zh) * 2018-08-13 2020-11-21 國立臺灣大學 使用口服肉鹼耐量試驗以測定一個體內氧化三甲胺產能之檢測方法
IL310994A (en) * 2021-08-25 2024-04-01 GARC?A SADA Fernando Preparations and methods for preventing or reducing the risk of metabolic syndrome

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3810994A (en) * 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
IT1156852B (it) 1978-07-10 1987-02-04 Sigma Tau Ind Farmaceuti Procedimento industriale per la preparazione del d'canforato della l carnitinammide e del d canforato della d carnitinammide e sue applicazioni
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
DE3463261D1 (en) 1983-12-28 1987-05-27 Sigma Tau Ind Farmaceuti Salts of l-carnitine and alkanoyl l-carnitines and process for preparing same
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
AU632992B2 (en) 1987-12-24 1993-01-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
IT1256705B (it) 1992-12-21 1995-12-12 Sigma Tau Ind Farmaceuti Procedimento per la preparazione di l-(-)-carnitina a partire da un prodotto di scarto avente opposta configurazione.
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
DK1218001T3 (da) 1999-09-03 2009-04-14 Sigma Tau Healthscience Spa Ultrafint L-carnitin, fremgangsmåder til fremstilling deraf, sammensætninger indeholdende det og fremgangsmåder til anvendelse deraf
DE10055940A1 (de) 2000-11-10 2002-05-29 Bayer Ag Neue Indanylidenverbindungen
AU2003275939A1 (en) 2002-11-08 2004-06-07 Novo Nordisk A/S Safe chemical uncouplers for the treatment of obesity
US8193240B2 (en) 2004-03-17 2012-06-05 Nestec S.A. Compositions and methods for reducing or preventing obesity
EP1774028A4 (en) * 2004-07-07 2008-05-07 Dana Farber Cancer Inst Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF OBESITY
RU2342115C2 (ru) 2006-12-28 2008-12-27 Федеральное государственное учреждение "Томский научно-исследовательский институт курортологии и физиотерапии Федерального агентства по здравоохранению и социальному развитию" (ФГУ "ТНИИКиФ Росздрава) Способ комплексного лечения детей с ожирением
US20110244059A1 (en) * 2008-08-20 2011-10-06 The University Of Medicine And Dentistry Of New Jersey Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor

Also Published As

Publication number Publication date
CA2954004C (en) 2023-10-10
FI3164125T3 (fi) 2023-12-11
WO2016004363A2 (en) 2016-01-07
US20210186918A1 (en) 2021-06-24
JP6887252B2 (ja) 2021-06-16
ES2965033T3 (es) 2024-04-10
EP3164125A2 (en) 2017-05-10
BR112016030983A8 (pt) 2021-07-06
EP3164125B8 (en) 2023-10-18
US20160000745A1 (en) 2016-01-07
AU2021200355B2 (en) 2022-11-17
EP3164125A4 (en) 2018-04-11
AU2021200355A1 (en) 2021-03-18
RU2017103450A (ru) 2018-08-07
RU2017103450A3 (es) 2019-02-13
AU2015283905B2 (en) 2020-10-22
BR112016030983A2 (pt) 2017-08-15
CN106604725B (zh) 2021-06-29
CN106604725A (zh) 2017-04-26
EP3164125B1 (en) 2023-09-06
JP2017523158A (ja) 2017-08-17
PT3164125T (pt) 2023-12-12
DK3164125T3 (da) 2023-12-18
US20240066001A1 (en) 2024-02-29
CO2017001025A2 (es) 2017-04-28
MX2017000222A (es) 2017-12-07
US10849872B2 (en) 2020-12-01
PE20170470A1 (es) 2017-05-14
WO2016004363A3 (en) 2016-03-03
JP2020143061A (ja) 2020-09-10
CA2954004A1 (en) 2016-01-07
JP7171644B2 (ja) 2022-11-15
HRP20231572T1 (hr) 2024-03-15
CN113387836A (zh) 2021-09-14
RU2745440C2 (ru) 2021-03-25
AU2015283905A1 (en) 2017-02-16

Similar Documents

Publication Publication Date Title
MX2021015661A (es) Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes.
PH12017502107A1 (en) Triazole agonists of the apj receptor
EA201591743A8 (ru) СТИМУЛЯТОРЫ sGC
MX2018000147A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45).
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX2018007418A (es) Compuestos de benzamida y sus usos como herbicidas.
MX2016015235A (es) Nuevos polipeptidos de union especifica y usos de los mismos.
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2014015197A (es) Tratamiento y prevencion de la enfermedad cardiovascular y trombosis.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
SG11201705450SA (en) Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases
EA033460B1 (ru) Замещенные [1,2,4]триазольные соединения в качестве фунгицидов
MX2017005249A (es) Compuestos para usarse en el tratamiento antihelmintico.
BR112017022022A8 (pt) Arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas)
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
MX2017004819A (es) Metodos de tratamiento de transtornos urológicos usando sarm.
MX2017001047A (es) Compuestos para usar en el tratamiento antihelmintico.
UA117524C2 (uk) Стимулятори рослин, їх застосування та спосіб стимуляції рослин
MA40388A (fr) Méthodes et compositions permettant de traiter l'obésité, prévenir la prise de poids, favoriser la perte pondérale, favoriser l'amincissement, et traiter ou prévenir le développement du diabète
WO2016069477A3 (en) A method of treating cancer that overexpresses topbp1
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
EA201790902A1 (ru) Способ получения комплекса железа(iii) с n-ацетиласпартилированным казеином и его применение в фармацевтических композициях
MA39718A (fr) Compositions et méthodes d'utilisation de celles-ci